

Clinical trial results for
advanced bladder or
urinary tract cancer
For certain previously untreated adults with
bladder cancer or urinary tract cancer
(urothelial carcinoma) that has spread or
cannot be removed by surgery
Clinical trial results for
advanced bladder or
urinary tract cancer
For certain previously untreated adults with
bladder cancer or urinary tract cancer
(urothelial carcinoma) that has spread or
cannot be removed by surgery
Actor portrayals.
In a clinical trial of 608 people with previously untreated advanced bladder or urinary tract cancer (urothelial carcinoma), 304 people were given OPDIVO + chemotherapy and 304 people were given chemotherapy alone. The chemotherapy medicines used for both groups in this clinical trial were cisplatin and gemcitabine.
Half the people were alive
Half the people were alive
People given OPDIVO + chemotherapy had a 22% lower risk of dying than those given chemotherapy alone.
People given OPDIVO + chemotherapy had a 38% lower risk of their cancer spreading, growing, or getting worse compared to those given chemotherapy alone.
OPDIVO + chemotherapy will not work for everyone. Individual results may vary.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For previously untreated adults with urinary tract cancer (urothelial carcinoma) that has spread or cannot be removed by surgery
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment when your urinary tract cancer has spread (metastatic) or cannot be removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment for adults whose urinary tract cancer has spread (metastatic) or cannot be removed by surgery.
It is not known if OPDIVO Qvantig is safe and effective in children.